Sylvester Comprehensive Cancer Center

  • AAML1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20161100

    SDG: Pediatric Cancer
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

    Eligibility Criteria - NCT02521493 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL1232 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20161103

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

    Eligibility Criteria - NCT02176967 *This information has been extracted from " www.clinicaltrials.gov"

  • ARST1431 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20170069

    SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

    Eligibility Criteria - NCT02567435 *This information has been extracted from " www.clinicaltrials.gov"

  • AALL15P1 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20170326

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

    Eligibility Criteria - NCT02828358 *This information has been extracted from " www.clinicaltrials.gov"

  • ADVL1622 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20170579

    SDG: Pediatric Cancer
    Disease Site(s):

    Kidney,Bones and Joints,Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.

    Eligibility Criteria - NCT02867592 *This information has been extracted from " www.clinicaltrials.gov"

  • X15015 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20170602

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    X15015: A Phase I Trial of Pevonedistat in combination with VXLD chemotherapy for adolescent and young adults with relapsed/refractory Acute Lymphoblastic Leukemia

    Eligibility Criteria - NCT03349281 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20170605

    SDG: Pediatric Cancer
    Disease Site(s):

    Ovary,Other Female Genital,Other Male Genital

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

    Eligibility Criteria - NCT03067181 *This information has been extracted from " www.clinicaltrials.gov"

  • T2016-003 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20170705

    SDG: Pediatric Cancer
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: THERAPEUTIC ADVANCES IN CHILDHOOD LEUKEMIA

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML

    Eligibility Criteria - NCT03263936 *This information has been extracted from " www.clinicaltrials.gov"

  • AALL1631 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20170840

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AALL1631:International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

    Eligibility Criteria - NCT03007147 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621: Pediatric MATCH - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20170841

    SDG: Pediatric Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Non-Hodgkin Lymphoma,Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

    Eligibility Criteria - NCT03155620 *This information has been extracted from " www.clinicaltrials.gov"

  • ADVL1521 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20180133

    SDG: Pediatric Cancer
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ADVL1521: A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

    Eligibility Criteria - NCT03190915 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20180624

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ANBL1531 : A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)) (IND# 134379)

    Eligibility Criteria - NCT03126916 *This information has been extracted from " www.clinicaltrials.gov"

  • AHEP1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20180800

    SDG: Pediatric Cancer
    Disease Site(s):

    Liver

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

    Eligibility Criteria - NCT03533582 *This information has been extracted from " www.clinicaltrials.gov"

  • T2017-002 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20190180

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: THERAPEUTIC ADVANCES IN CHILDHOOD LEUKEMIA

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    T2017-002 : A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

    Eligibility Criteria - NCT03817320 *This information has been extracted from " www.clinicaltrials.gov"

  • ACNS1422 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20190523

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

    Eligibility Criteria - NCT02724579 *This information has been extracted from " www.clinicaltrials.gov"

  • ACNS1721 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20190524

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

    Eligibility Criteria - NCT03581292 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1532 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20190525

    SDG: Pediatric Cancer
    Disease Site(s):

    Prostate,Other Urinary

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial Of Accelerated Versus Standard BEP Chemotherapy For Patients With Intermediate And Poor-Risk Metastatic Germ Cell Tumours

    Eligibility Criteria - NCT02582697 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL 1821 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20190652

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System,Other Endocrine System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma

    Eligibility Criteria - NCT03794349 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191014 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20191014

    SDG: Pediatric Cancer
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

    Eligibility Criteria - NCT03914625 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160415 - St. George Sara

  • Investigator:
    Sara St. George
    RCname Email

    Coordinator:

    IRB: 20160415

    SDG: Population Sciences
    Disease Site(s):

    Multiple

    Sponsor: NHLBI

    Enrolling Sites:

    Community Clinics
    JMH
    Sylvester
    UMH

    Title:

    St. George K01: Family-based eHealth Obesity Prevention Intervention for Hispanic Adolescents

    Eligibility Criteria - NCT03986190 *This information has been extracted from " www.clinicaltrials.gov"

  • KTE-C19-104 - Ziga, Edward

  • Investigator:
    Edward Ziga
    RCname Email

    Coordinator:

    IRB: 20160129

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Kite

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

    Eligibility Criteria - NCT02625480 *This information has been extracted from " www.clinicaltrials.gov"